Kathy S. Albain, MD, from Loyola University Chicago, discusses gene assays as they relate to the treatment of patients with breast cancer.
Kathy S. Albain, MD, medical oncologist, Loyola University Chicago, professor, Stritch School of Medicine, director, Breast Clinical Research Program, Thoracic Oncology Research Program, Cardinal Bernardin Cancer Center, discusses gene assays as they relate to the treatment of patients with breast cancer.
In her presentation at the 12th International Congress on the Future of Breast Cancer from July 18-20, 2013, in Huntington Beach, CA, Albain first discussed the fact that a certain population of patients with large numbers of positive nodes or large tumors can be cured with surgery. Research is being conducted to find these patients, as well as those who have small tumors with a high propensity for metastases. All of the research to date has further demonstrated the necessity for a combination tool that can incorporate many patient factors.
A 21-gene (Oncotype DX) assay only helps the decision-making process, Albain says. However, Albain does not order a 21-gene assay in all patients, especially those who are sure about how they want to be treated or if urgent treatment is necessary. Often times, clinical factors and biologic factors are discordant, Albain says, reinforcing the need for additional research.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More